A282 DOES SERUM ADALIMUMAB LEVEL CORRELATE WITH DISEASE SEVERITY IN PATIENTS WITH CROHN’S DISEASE?
| Autor: | J C Gregor, M Gandhi, L Stitt |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
musculoskeletal diseases
medicine.medical_specialty Crohn's disease business.industry medicine.disease Gastroenterology humanities Poster Presentations Text mining Disease severity Internal medicine Severity of illness medicine Adalimumab In patient Trough Concentration Dosing interval business skin and connective tissue diseases medicine.drug |
| Popis: | AIMS: Tests measuring serum adalimumab levels are not widely available. We aim to evaluate whether serum adalimumab levels correlate with disease severity in patients with Crohn’s disease. Additionally, as the test is expensive, we aim to see if clinical and biochemical markers can be used as a surrogate for adalimumab levels. METHODS: A retrospective chart review was performed on Crohn’s disease patients that had a measured adalimumab level. Sixty-five patients were identified between January 2015 and January 2016. Disease severity was determined using the Harvey-Bradshaw Index. Patients were stratified based on their dosing intervals. RESULTS: For patients with weekly dosing (n=16), 8 were in remission. Mean trough adalimumab levels for remission and active disease groups were 8.8 and 7.3 respectively. There was no statistically significant relationship between trough adalimumab level and disease severity, weight, CRP or albumin. For patients with biweekly dosing (n=49), 32 were in remission. Mean trough adalimumab levels for remission and active disease groups were 8.5 and 6.1 respectively. The correlation between trough adalimumab level and weight was -0.44 (p=0.002). Similarly, the correlation between trough adalimumab level and CRP was -0.39 (p=0.031). Trough adalimumab level did not have a statistically significant relationship with albumin or disease severity. CONCLUSIONS: In both groups, patients in remission tended to have higher trough adalimumab levels. In patients with biweekly dosing, higher drug levels correlated with lower patient weight and lower CRP values. This likely stems from higher consumption of adalimumab with active inflammation present in active disease. The absence of statistically significant relationships for patients with weekly adalimumab dosing is likely a factor of the smaller sample size. Ultimately, larger study with prospective data may yield more helpful information. FUNDING AGENCIES: None |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|